
This study aimed to compare the effects of SGLT2 inhibitors and dipeptidyl peptidase‐4 inhibitors on ectopic fat accumulation and tissue-specific insulin sensitivity in patients with type 2 diabetes and non-alcoholic fatty liver disease. 44 patients were enrolled and randomly assigned to receive either empagliflozin or sitagliptin for 12 weeks. The primary endpoint was the change in intrahepatic lipid content. The study found that empagliflozin significantly improved hepatic steatosis compared to sitagliptin, and this may protect against subsequent hepatic insulin resistance. It suggests that early administration of SGLT2 inhibitors is preferable for T2D patients with NAFLD.
Like
Save
Share